



ASX announcement

## Settlement of Manufacturing Claims

**Melbourne, Australia; 25 October, 2018:** Patrys Limited (**ASX: PAB**), a clinical stage biotechnology company, is pleased to announce that it has come to a negotiated settlement with its insurers regarding the failed manufacturing runs for PAT-SM6 in 2014 and 2015.

The settlement of an additional A\$3 million was reached with no admission of liability from the insurers. Payment will be received by Patrys within 30 days.

**-Ends-**

**For further information, please contact:**

Patrys Limited:

James Campbell  
Chief Executive Officer  
P: +61 3 96703273  
[info@patrys.com](mailto:info@patrys.com)

Patrys IR:

Ben Walsh  
WE Buchan  
P: +61 2 9237 2801  
[bwalsh@buchanwe.com.au](mailto:bwalsh@buchanwe.com.au)

**About Patrys Limited:**

Based in Melbourne, Australia, Patrys (ASX: PAB) is focused on the development of antibodies as therapies for a range of different cancers. Patrys has a pipeline of anti-cancer antibodies for both internal development and as partnering opportunities. More information can be found at [www.patrys.com](http://www.patrys.com).